27 July 2020
AZD0466 trial opens MD Anderson Cancer Center as a site
9 July 2020
New Australian site opening for DEP® trials
29 June 2020
DEP® irinotecan boosts immuno-oncology in colon cancer models
23 June 2020
Multiple DEP® products showcased at AACR 2020
18 June 2020
Starpharma to present at OTCQX Virtual Investor Conference
17 June 2020
DEP® lutetium effective in human prostate cancer model
16 June 2020
VivaGel® BV launched in central and eastern European countries
16 June 2020
Notice of initial substantial holder
26 May 2020
Notice of initial substantial holder
14 May 2020
Shareholder Update May 2020
7 May 2020
DEP® irinotecan phase 2 commences after positive phase 1 results
5 May 2020
Starpharma presents at Macquarie Australia Conference

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.